TORONTO,CANADA – March 30, 2021 – Cybin Inc. (NEO:CYBN)(OTCQB:CLXPF) (“Cybin” or the “Company”), a biotechnology company focused on progressing psychedelic therapeutics, today announced key senior management changes to lead the buildout of its development and clinical operations in the United States and Europe. Effective immediately, Alexander Belser, PhD, will serve as Chief Clinical Officer…


Previous articlePT237 – Dena Justice – Finding the Frequency of Safety
Next articleLemon Tek to the Rescue for Magic Mushroom Nausea?